Form 8-K - Current report:
SEC Accession No. 0001628280-24-034143
Filing Date
2024-08-01
Accepted
2024-08-01 16:10:58
Documents
16
Period of Report
2024-07-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vir-20240729.htm   iXBRL 8-K 30211
2 EX-99.1 a20240801-q2ex991earningsr.htm EX-99.1 111695
7 virlogoa.jpg GRAPHIC 25904
  Complete submission text file 0001628280-24-034143.txt   352596

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vir-20240729.xsd EX-101.SCH 2258
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vir-20240729_def.xml EX-101.DEF 15302
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vir-20240729_lab.xml EX-101.LAB 26870
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vir-20240729_pre.xml EX-101.PRE 16021
18 EXTRACTED XBRL INSTANCE DOCUMENT vir-20240729_htm.xml XML 3339
Mailing Address 1800 OWENS STREET SUITE 900 SAN FRANCISCO CA 94158
Business Address 1800 OWENS STREET SUITE 900 SAN FRANCISCO CA 94158 415-906-4324
Vir Biotechnology, Inc. (Filer) CIK: 0001706431 (see all company filings)

EIN.: 812730369 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39083 | Film No.: 241166745
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)